LY2510924: a CXCR4 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 25102787 |
| SCHEMBL ID | 13343973 |
| MeSH ID | M000602687 |
| Synonym |
|---|
| S8505 |
| SCHEMBL13343973 |
| l53sqf2i6g , |
| unii-l53sqf2i6g |
| l-lysinamide, l-phenylalanyl-l-tyrosyl-n6-(1-methylethyl)-l-lysyl-d-arginyl-3-(2-naphthalenyl)-l-alanylglycyl-d-alpha-glutamyl-n6-(1-methylethyl)-, (7->1)-lactam |
| ly-2510924 |
| 1088715-84-7 |
| l-lysinamide, l-phenylalanyl-l-tyrosyl-n6-(1-methylethyl)-l-lysyl-d-arginyl-3-(2-naphthalenyl)-l-alanylglycyl-d-.alpha.-glutamyl-n6-(1-methylethyl)-, (7->1)-lactam |
| 1642567-68-7 |
| ly 2510924 [who-dd] |
| ly2510924 |
| cid 25102787 |
| Q27282719 |
| (2s,5s,8s,11r,14s,20r)-n-[(2s)-1-amino-1-oxo-6-(propan-2-ylamino)hexan-2-yl]-2-benzyl-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-14-(naphthalen-2-ylmethyl)-3,6,9,12,15,18,23-heptaoxo-8-[4-(propan-2-ylamino)butyl]-1,4,7,10,13,16,19- |
LY2510924 is a peptide antagonist, which blocks stromal cell-derived factor-1 (SDF1) from CXCR4 binding.
| Excerpt | Reference | Relevance |
|---|---|---|
| "LY2510924 is a peptide antagonist, which blocks stromal cell-derived factor-1 (SDF1) from CXCR4 binding." | ( A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Conkling, P; Galsky, MD; Polzer, J; Raddad, E; Roberson, S; Saleh, M; Stille, JR; Thornton, D; Vogelzang, NJ, 2014) | 1.45 |
LY2510924 was a peptide antagonist of CXCR4, combined with sunitinib. It had antileukemia effects as monotherapy as well as in combination with chemotherapy.
| Excerpt | Reference | Relevance |
|---|---|---|
| " LY2510924 had antileukemia effects as monotherapy as well as in combination with chemotherapy." | ( Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Andreeff, M; Cho, BS; Cortes, J; Davis, RE; Konoplev, S; Konopleva, M; Ma, W; Marszalek, JR; McQueen, T; Mu, H; Peng, SB; Protopopova, M; Thornton, DE; Wang, Z; Zeng, Z, 2015) | 1.57 |
| " In this randomized Phase 2 trial, we evaluated the safety and efficacy of LY2510924 (LY), a peptide antagonist of CXCR4, combined with sunitinib (SUN) in the first-line treatment of advanced renal cell carcinoma (RCC)." | ( A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Arrowsmith, ER; Crane, EJ; Flynt, A; Hainsworth, JD; Hamid, O; Mace, JR; Polzer, J; Reeves, JA; Roberson, S; Stille, JR, 2016) | 0.9 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (50.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (37.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||